



NEW YORK CITY DEPARTMENT OF

HEALTH AND MENTAL HYGIENE

Oxiris Barbot, MD

Commissioner

TO: All Borough Presidents
All Community Boards

FROM: Christian Diaz 
Assistant Commissioner, Finance, Administration and Services
Center for Health Equity and Community Wellness
Department of Health and Mental Hygiene

SUBJECT: Notice of Joint Public Hearing, December 9, 2019: re Amendment of the concession agreement between the New York City Department of Health and Mental Hygiene and OptumRx Discount Card Services, LLC (formerly known as Catamaran Discount Card Services, LLC) to develop, operate and administer the NYC Drug Discount Card Program available to all New York City residents

DATE: November 20, 2019

NOTICE OF A JOINT PUBLIC HEARING of the Franchise and Concession Review Committee and the New York City Department of Health and Mental Hygiene to be held on December 9, 2019 at 2 Lafayette Street, 14th Floor Auditorium, Borough of Manhattan, commencing at 2:30 p.m. relative to:

AMENDMENT of the concession agreement between the New York City Department of Health and Mental Hygiene and OptumRx Discount Card Services, LLC (formally known as Catamaran Discount Card Services, LLC) for the development, operation and administration of the NYC Drug Discount Card Program available to all New York City residents. The amendment extends the expiration date of the concession agreement from August 16, 2018 to December 31, 2021.

A draft copy of the amendment may be reviewed or obtained at no cost commencing November 22, 2019 through December 9, 2019, between the hours of 9:00 a.m. and 5 p.m., excluding weekends and holidays at the New York City Department of Health and Mental Hygiene, Office of Contracts, located at 42-09 28th Street, 17th Floor, Long Island City, NY 11101.

This location is accessible to individuals using wheelchairs or other mobility devices. For further information on accessibility or to make a request for accommodations, such as sign language interpretation services, please contact the Mayor's Office of Contract Services (MOCS) via e-mail at DisabilityAffairs@mocs.nyc.gov or via phone at (212) 788-0010. Any person requiring reasonable accommodation for the public hearing should contact MOCS at least three (3) business days in advance of the hearing to ensure availability. 

TELECOMMUNICATION DEVICE FOR THE DEAF (TDD) 212-504-4115

CONCESSION AGREEMENT RECOMMENDATION FOR AWARD MEMORANDUM COVER SHEET

(Attach, in the following order, applicable CRFA Memo, Responsibility Determination Form, approved CPSR Cover Sheet and, if the selection procedure was not CSB, the CPSR Memo and CCPO Memo (if applicable))

AGENCY: NYC Department of Health and Mental Hygiene ("DOHMH")	RECOMMENDED CONCESSIONAIRE Name: <u>OptumRx Discount Card Services, LLC (f/k/a Catamaran Discount Card Services, LLC)</u> Address: <u>1600 McConnor Parkway, Schaumburg, IL 60173</u> Telephone # <u>720-482-3726</u> <input checked="" type="checkbox"/> EIN <input type="checkbox"/> SSN # <u>31-1728846</u> Not-for-Profit Organization <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No Certified by DSBS as M/WBE <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No	CONCESSION TITLE/ DESCRIPTION: To develop, operate and administer the NYC Drug Discount Card Program available to all New York City residents. CONCESSION I.D.# <u>11HM000701R2T03</u>
# VOTES required for proposed action = <u>4</u> <input type="checkbox"/> N/A		

LOCATION OF CONCESSION SITE(S*) Address _____ N/A
*Attach additional sheet **Borough** _____ **C.B.** _____ **Block #** _____ **Lot #** _____

SELECTION PROCEDURE
 (*CCPO approval of CRFA required)

Competitive Sealed Bids
 Competitive Sealed Proposals* (FCRC approved Agency request to deviate from final recommendation of the Selection Committee on ___/___/___.)
 Different Selection Procedure: * (Sole Source Agreement Other Amendment to the existing concession agreement between DOHMH and OptumRx Discount Card Services, LLC (formerly known as Catamaran Discount Card Services, LLC.)
 > FCRC approved different selection procedure on 10/12/2018
 Negotiated Concession*

<p align="center">CONCESSION AGREEMENT TERM</p> Initial Term: From <u>02/17/2015</u> To <u>08/16/2018</u> Renewal Option(s) Term: <u>None</u> Total Potential Term: <u>08/16/2018 to 12/31/2021</u> <input type="checkbox"/> * >20 years – FCRC unanimously approved term on ___/___/___	<p align="center">ANNUAL REVENUE (Check all that apply) (<input type="checkbox"/> Additional sheet (<input type="checkbox"/> s) attached)</p> <input type="checkbox"/> Annual Fee(s) \$ _____ <input type="checkbox"/> % Gross Receipts _____% <input type="checkbox"/> The Greater of Annual Minimum Fee(s of \$_____ v. _____% of Gross Receipts <input checked="" type="checkbox"/> Other <u>DOHMH is required to operate a drug discount card program available to all NYC residents pursuant to Local Law 19 of 2005. In 2011, OptumRx was awarded a concession to develop, operate, and administer the NYC Drug Discount Card Program without charge to the City. Although there is no revenue received by the City, the benefit to DOHMH is the receipt of these services without a cost to the City. OptumRx will continue to operate and administer the Program at no charge to the City.</u>
---	--

NOTIFICATION REQUIREMENTS

Subject concession was awarded by CSB or CSP. YES NO

If YES, check the applicable box(es) below:

The subject concession is a Significant Concession and the Agency completed its consultations with each affected CB/BP regarding the scope of the solicitation by ___/___/___, which was at least 30 days prior to its issuance.

The subject concession is a Significant Concession and the Agency included this concession in the Agency's Plan and completed consultations with each affected CB/BP pursuant to §1-10 of the Concession Rules.

The subject concession was determined not to be a Major Concession and the Agency sent notification of such determination to each affected CB/BP by ___/___/___, which was at least 40 days prior to issuance of the solicitation.

If NO, check the applicable box below:

The Agency certifies that each affected CB/BP received written notice by 08/29/2018, which was at least 40 days in advance of the FCRC meeting on 10/12/2018 at which the agency sought and received approval to use a different selection procedure.

The Agency certifies that each affected CB/BP received written notice on ___/___/___, at the time that a notice of intent to enter into negotiations was published for the subject concession, and provided a copy of such notification to the members of the Committee within five days on ___/___/___.

The Agency certifies that based on exigent circumstances the FCRC unanimously approved waiver of advance written notice to each affected CB/BP on ___/___/___.

Law Department approved concession agreement on _____

Award is a major concession. YES NO

If YES, award was approved pursuant to Sections 197-c and 197-d of the NYC Charter as follows:

CPC approved on ___/___/___ City Council approved on ___/___/___ or N/A

AUTHORIZED AGENCY STAFF

This is to certify that the information presented herein is accurate and that I find the proposed concessionaire to be responsible and approve of the award of the subject concession agreement.

If the concession was awarded by other than CSB or CSP, additionally check the applicable box below:

The concession was approved by the FCRC on ___/___/___.

The concession was not subject to the approval of the FCRC because it has a term of <30 days and is not subject to renewal.

Name _____ **Title** _____

Signature _____ **Date** ___/___/___

CERTIFICATE OF PROCEDURAL REQUISITES

This is to certify that the agency has complied with the prescribed procedural requisites for award of the subject concession agreement.

Signature _____ **Date** ___/___/___

City Chief Procurement Officer

**RECOMMENDATION FOR AWARD OF CONCESSION AGREEMENT MEMORANDUM:
CONCESSION AGREEMENT AWARDED BY OTHER THAN CSB OR CSP**

SUMMARY OF PROPOSED CONCESSION USE (Attach Proposed Agreement)

New York City Department of Health and Mental Hygiene ("DOHMH") is seeking Franchise and Concession Review Committee ("FCRC") approval to use a different procedure, pursuant to Section 1-16 of the Concession Rules of the City of New York ("Concession Rules"), to amend its current Concession Agreement with OptumRx Discount Card Services, LLC. (formerly known as Catamaran Discount Card Services, LLC) to develop, operate and administer the NYC Drug Discount Card Program available to all New York City residents.

Instructions: Provide all information requested below; check all applicable boxes.

A. SELECTION PROCEDURE

Sole Source

Other ***Describe:*** DOHMH is seeking FCRC approval to use a different procedure, pursuant to Section 1-16 of the Concession rules, to amend its current Concession Agreement with OptumRx Discount Card Services, LLC. (formerly known as Catamaran Discount Card Services, LLC) for the development, operation and administration of the NYC Drug Discount Card Program available to all New York City residents.

B. NEGOTIATIONS

Instructions: Describe the nature of negotiations conducted, including negotiations with respect to the amount of revenue offered.

During negotiations it became apparent that a second extension of 18-months as originally anticipated was not going to be sufficient to complete the RFP process and enter into a new concession agreement. During the first extension of 18 months, DOHMH conducted extensive research to inform the next iteration of the Big Apple RX -card, identified potential strategies to strengthen opioid controls, and worked with legal teams from both the City and the concessionaire to resolve issues concerning transition planning. In that time, DOHMH also worked diligently to solidify a provision to carve out opioid prescriptions. The foregoing efforts demanded extensive time, technical and legal expertise, negotiation with the existing concessionaire, OptumRx Discount Card Services, LLC., and input from agency and city leadership. Furthermore, the development and review of the RFP was time and resource intensive. Due to the now crowded landscape of prescription drug discount card programs and skyrocketing prices for prescription drugs, the City anticipates the number of interested RFP respondents, time needed for review and selection, and negotiation of a final concession agreement would considerably lengthen the time needed for the RFP process. Therefore, DOHMH is requesting an extension of the current concession from August 16, 2018 to December 31, 2021.

DOHMH has had a professional relationship with OptumRx Discount Card Services, LLC. since 2015. While there is no actual contract in place as of August 2018, OptumRx has been operating in good faith, and is willing to continue to operate and administer the NYC Drug Discount Card Program during the requested extension period. The amended Concession Agreement would extend the expiration date of the current Concession Agreement from August 16, 2018 to December 31, 2021 and would modify the scope of services to prohibit use of the Big Apple RX card for certain opioid prescriptions. DOHMH intends to undertake a new RFP process to solicit a new concessionaire to develop, operate and administer the NYC Drug Discount Card Program, and anticipates a new award will be in place by the expiration of this extension period.

C. BASIS FOR AWARD (If sole source award, attach the offer; if other than a sole source award, attach the three highest rated offers, if applicable.)

The agency determined that amendment of the concession is in the best interest of the City because:

DOHMH believes that the City will be best served by extending the Concession Agreement with OptumRx Discount Card Services, LLC., to enable the residents of New York City to continue to have access to pharmaceutical drugs at discount prices without interruption while DOHMH undertakes a new RFP process to solicit a concessionaire to develop, operate and administer the NYC Drug Discount Card Program.

Currently, over 1 million IDNYC cards have been issued by the City with the BigAppleRX benefit feature on the card, enabling cardholders to purchase pharmaceutical drugs at discount prices provided by OptumRx (also referred to as "BigAppleRX provider"). Those IDNYC cards will remain in effect until 5 years after their effective date. Given that the BigApple RX benefit is linked to these IDNYC cards, transitioning to a new provider will be administratively complicated and time consuming. Therefore, DOHMH believes that the City will be best served by an extension to the current concession agreement with OptumRx to enable the residents of New York City to continue to have access to pharmaceutical drugs at discount prices without interruption while DOHMH initiates a new RFP process to select a new concessionaire.

D. PUBLIC HEARING **N/A – Subject award NOT a significant concession**

1. Publication & Distribution of Public Hearing Notice

Subject concession is a **Citywide** concession and Agency hereby certifies that a notice containing a summary of the terms and conditions of the proposed concession and stating the time, date and location of the public hearing was published once in the City Record on November 22, 2019 which was not less than 15 days prior to the hearing date or a shorter period approved by the CCPO and was given to each affected CB-BP and the Committee Members on December 9, 2019, which was not less than 15 days prior to the hearing date. Agency also published a public hearing notice twice in the two newspapers indicated below. A copy of each such notice was sent to each affected CB-BP by November 20, 2019.

New York Post, a NYC citywide newspaper on December 4, 2019 and December 6, 2019

New York Daily, a NYC citywide newspaper on December 4, 2019 and December 6,

2019
OR

Subject concession is **NOT a Citywide** concession and Agency hereby certifies that a notice containing a summary of the terms and conditions of the proposed concession and stating the time, date and location of the public hearing was published once in the City Record on ___/___/___, which was not less than 15 days prior to the hearing date or a shorter period approved by the CCPO and was given to each affected CB-BP and the Committee Members on ___/___/___, which was not less than 15 days prior to the hearing date. Agency additionally published a public hearing notice and summary of the terms and conditions of the proposed agreement twice in two newspapers indicated below. A copy of each such notice containing a summary of the terms and conditions of the proposed agreement was sent to each affected CB-BP by ___/___/___.

_____, a NYC local newspaper published in the affected borough(s) on ___/___/___ and ___/___/___.

_____, a NYC local newspaper published in the affected borough(s) on ___/___/___ and ___/___/___.

2. Public Hearing Date, Exception to Public Hearing Requirement

A Public Hearing was conducted on December 9, 2019.

OR

The Agency certifies that the total annual revenue to the City from the subject concession does not exceed one million dollars and a Public Hearing was not conducted because, pursuant to §1-13(q)(2) of the Concession Rules, the Agency gave notice of the hearing and did not receive any written requests to speak at such hearing or requests from the Committee that the Agency appear at the hearing. Furthermore, the Agency certifies that it published a notice in the City Record canceling such hearing on ___/___/___ and sent a copy of that notice to all Committee Members.

CITY OF NEW YORK

FRANCHISE AND CONCESSION REVIEW COMMITTEE

(Cal. No. X)

RESOLVED, that the Franchise and Concession Review Committee authorizes the New York City Department of Health and Mental Hygiene (“DOHMH”) to utilize a different procedure, pursuant to Section 1-16 of the Concession Rules of the City of New York, to amend the concession agreement with OptumRx Discount Card Services, LLC (formerly known as Catamaran Discount Card Services, LLC) to develop, operate and administer the NYC Drug Discount Card Program available to all New York City residents. The amended concession agreement, among other things, extends the expiration date of the concession agreement from August 16, 2018 to December 31, 2021.

**THIS IS A TRUE COPY OF THE RESOLUTION ADOPTED BY THE
FRANCHISE AND CONCESSION REVIEW COMMITTEE ON**

December 11, 2019

Date: _____

Signed: _____

Title: Director of the Mayor’s Office of Contract Services

**SECOND AMENDMENT TO
FIRST RENEWAL AGREEMENT**

of

CONCESSION AGREEMENT

BETWEEN

OPTUMRX DISCOUNT CARD SERVICES, LLC

AND

CITY OF NEW YORK

Acting by and through its

DEPARTMENT OF HEALTH & MENTAL HYGIENE

for

**THE OPERATION AND ADMINISTRATION OF THE
NEW YORK CITY PRESCRIPTION DRUG DISCOUNT CARD PROGRAM**

Concession ID #: 19HO011401R0X00

SECOND AMENDMENT TO THE FIRST RENEWAL AGREEMENT (“Second Amendment”) effective as of August 16, 2018 (“the Effective Date”), between the City of New York (“City”) acting by and through its **Department of Health and Mental Hygiene** (“the Department” or “DOHMH”), having its principal office at 42-09 28th Street, Long Island City, New York 11101, and **OptumRx Discount Card Services, LLC**, a Delaware pharmacy benefit management company (“Concessionaire” or “OptumRx”), having a principal office at 1600 McConnor Parkway, Schaumburg, Illinois 60173 (each “a Party”, together, “the Parties”).

WITNESSETH

WHEREAS, the Department, pursuant to Local Law 19 of 2005 “Prescription Drug Discount Card Act” (“Local Law 19”), is required to develop a drug discount card program to be made available to all City residents, known as the NYC Prescription Drug Discount Card Program (“the Program”); and

WHEREAS, Local Law 19 allows the Department to enter into an agreement for the services of a Program administrator, and the City has determined that such agreement shall be in the form of a concession; and

WHEREAS, the Department entered into a concession agreement with HealthTran, LLC (d/b/a HealthTrans), as concessionaire (Concession ID#: 11HM000700R0X00), to develop, operate and administer the Program for the initial term of three (3) years, from February 17, 2011 through February 16, 2014 (“Initial Term”), with the option to renew for one or more periods of twelve (12) months that in the aggregate do not exceed three (3) years (“Original Concession Agreement”); and

WHEREAS, during the Initial Term of the Original Concession Agreement, the concessionaire was acquired by SXC Health Solutions Corp., which subsequently changed its name to Catamaran Corporation, and as a result thereof the concessionaire’s name was changed to Catamaran Corporation; and

WHEREAS, the Original Concession Agreement was renewed for a first renewal term of one (1) year, from February 17, 2014 through February 16, 2015, by amending and restating the Agreement and including therein the remaining renewals that in the aggregate do not exceed two (2) years (“First Renewal Agreement”, Concession ID#: 11HM000701R1X00); and

WHEREAS, the concessionaire in the First Renewal Agreement was Catamaran PBM of Colorado, a subsidiary of Catamaran Corporation, and during the First Renewal Agreement the concessionaire changed its name to Catamaran Discount Card Services, LLC (hereinafter “Catamaran”); and

WHEREAS, the First Renewal Agreement was renewed for a second renewal term of two (2) years, from February 17, 2015 through February 16, 2017, by a Notice to Renew letter provided

in accordance with the provisions of the First Renewal Agreement (“Second Renewal Agreement”, Concession ID#:11HM000701R2X00); and

WHEREAS, during the term of the Second Renewal Agreement, the concessionaire changed its name from Catamaran Discount Card Services, LLC to OptumRx Discount Card Services, LLC, due to the acquisition of Catamaran by OptumRx; and

WHEREAS, upon the expiration of the Second Renewal Agreement, there were no further renewals provided for under the First Renewal Agreement; and

WHEREAS, the Department intends to undertake a competitive request for proposal (“RFP”) process to solicit a new concessionaire to operate and administer the Program; and

WHEREAS, in order for the City to continue to comply with Local Law 19 and serve the needs of NYC residents without interruption during the RFP process, the Department sought and received authorization from the Franchise and Concession Review Committee (“FCRC”) to use a different procedure to enter into an Amendment to the First Renewal Agreement (Concession ID#: 11HM000701R2T01), pursuant to which OptumRx continued to operate and administer the program for an additional eighteen (18) months, from February 16, 2017 to August 16, 2018 (“First Amendment”); and

WHEREAS, the Department anticipated releasing an RFP and selecting a new concessionaire on or before August 2018, but because of unforeseen delays in the development of the RFP due to changes in the scope of services, the Department now anticipates that a new concessionaire will be in place by December 31, 2021; and

WHEREAS, in order for the City to continue to comply with Local Law 19 and serve the needs of NYC residents during the RFP process, it will be necessary to extend the First Renewal Agreement from August 16, 2018 through December 31, 2021 and to amend the scope of services (this Second Amendment) to continue to provide such services to NYC residents without interruption; and

WHEREAS, OptumRx is willing to continue to provide the services of operating and administering the Program, and the Parties desire to amend the terms of the First Renewal Agreement, subject to and in accordance with the terms of this Second Amendment; and

WHEREAS, the FCRC has authorized the Department to use a different procedure to enter into this Second Amendment.

NOW THEREFORE, in consideration of the mutual promises herein contained, the Parties hereby agree as follows:

1. Unless otherwise noted, all capitalized terms referenced herein shall have the meanings ascribed thereto in the First Renewal Agreement.
2. Section 3.03 of the First Renewal Agreement, as added by the First Amendment, is hereby deleted in its entirety and replaced with the following”

“Section 3.03 Extension: This Agreement shall be extended from February 16, 2017, the last day of the second Renewal Term exercised pursuant to Section 3.02 above, to August 16, 2018, for a period of eighteen (18) months, unless sooner terminated pursuant to the provisions hereof (“First Amendment Extension Term”). This Agreement shall be extended from August 16, 2018 to December 31, 2021, unless sooner terminated pursuant to the provisions hereof (“Second Amendment Extension Term”). Notwithstanding any inconsistent provision of this Agreement, the Services shall continue uninterrupted and in accordance with the provisions of this Agreement during the First Amendment and Second Amendment Extension Terms.”

3. Subsection (a) of Article 22 of the First Renewal Agreement is hereby deleted in its entirety and replaced with the following:

(a) All notices, directions and communications by either party shall be in writing and, except as otherwise specified in this Agreement, directed to the address of the parties as follows:

New York City
Dept. of Health & Mental Hygiene
42-09 28th Street, WS 12-10
Long Island City, NY 11101

Attn: Cynthia Mont-Burbon
Director of Contracts
Prevention & Primary Care Administration

OptumRx Discount Card Services, LLC

1600 McConnor Parkway
Schaumburg, Illinois 60173

Attn: Michael Oshins
Vice President,
Sales & Business Development
Pharmacy Discount Services

With a copy to:

Vernon Blair
Deputy General Counsel
42-09 28th Street, WS 14-93
Long Island City, NY 11101

With a copy to:

General Counsel
1600 McConnor Parkway
Schaumburg, Illinois 60173

4. Exhibit B of the First Renewal Agreement (The Scope of Services and Roles and Responsibilities of Each Party) (attached for convenience) is hereby amended as outlined in Exhibit B-1 of the First Renewal Agreement (The Amended Scope of Services and Roles and Responsibilities of Each Party) attached hereto and made a part hereof. All references in the First Renewal Agreement to “Exhibit B,” the “Scope of Services”, or the “Services” shall be deemed to also refer to Exhibit B-1.
5. Except as expressly amended herein, all terms and conditions of the First Renewal Agreement, as previously amended, shall remain unchanged and in full force and effect.

6. This Amendment shall take effect on, and shall be retroactive to, August 16, 2018, subject to compliance with all applicable processes including registration with the New York City Comptroller pursuant to Section 328 of the New York City Charter.

Attachments

Exhibit B to First Renewal Agreement: The Scope of Services and Roles and Responsibilities of Each Party (attached for convenience)

Exhibit B-1 to First Renewal Agreement: The Amended Scope of Services and Roles and Responsibilities of Each Party

Attachment I to Exhibit B-1: Exceptions to Definition of Opioids

IN WITNESS WHEREOF, the City and the Concessionaire have caused this Second Amendment to be executed in triplicate by their duly authorized representatives as of the day and year written below.

**CITY OF NEW YORK
DEPARTMENT OF HEALTH AND MENTAL HYGIENE**

BY: _____

NAME: Judi R. Soehren
TITLE: Agency Chief Contracting Officer

Date: _____

**OPTUMRX
DISCOUNT CARD SERVICES, LLC**

By: _____

NAME: _____
TITLE: _____

Date: _____

APPROVED AS TO FORM
CERTIFIED AS TO LEGAL AUTHORITY

Acting Corporation Counsel

Date: _____

NYC DEPARTMENT OF HEALTH AND MENTAL HYGIENE

STATE OF NEW YORK)

ss:

COUNTY OF NEW YORK)

On this _____ day of _____ 2019 before me personally came Judi Soehren, to me known and known to me to be the Agency Chief Contracting Officer of the **Department of Health and Mental Hygiene** of the City of New York, the person described in who, as Agency Chief Contracting Officer executed, the foregoing agreement, and she duly acknowledged to me that she executed the same on behalf of the City of New York and DOHMH of Health and Mental Hygiene for the purpose herein mentioned.

Notary Public or Commissioner of Deeds

OPTUMRX DISCOUNT CARD SERVICES, LLC

STATE OF)

ss:

COUNTY OF)

On this ____ day of _____, 2019 before me personally came _____ who being by me duly sworn, did depose and say that (s)he resides in the City of _____; that (s)he is the _____ of **OptumRx Discount Card Services, LLC**, the corporation described in and which executed the foregoing instrument; that (s)he knows the seal of said Corporation; that the seal affixed to the said instrument is such corporate seal; that it was so affixed by order of the Board of Directors of said Corporation; and that (s)he signed his/her name thereto by like order for the purposes therein mentioned.

Notary Public or Commissioner of Deeds

AFFIRMATION

The undersigned proposer or bidder Affirms and declares that said proposer or bidder is not in arrears to the City of New York upon debt, contract or taxes and is not a defaulter, as surety or otherwise, upon obligation to the City of New York, and has not been declared not responsible, or disqualified, by any agency of the City of New York, nor is there any proceeding pending relating to the responsibility or qualification of the proposer or bidder to receive public contracts except

_____.

Full name of proposer or bidder: _____

Address: _____

City: _____ State: _____ Zip: _____

CHECK ONE AND INCLUDE APPROPRIATE NUMBER:

() A -- Individual or Sole Proprietorship
SOCIAL SECURITY NUMBER

() B -- _____-_____-_____
Partnership, Joint Venture or other unincorporated organization
Employer Identification Number

() C -- _____-_____-_____
Corporation
Employer Identification Number
_____ - _____ - _____

By: _____
Signature

Title

If a corporation, place seal here:

Must be signed by an officer or duly authorized representative.

Under the Federal Privacy Act the furnishing of Social Security Number by bidders on City contracts is voluntary. Failure to provide a Social Security Number will not result in a bidder's disqualification. Social Security Numbers will be used to identify bidders, proposers or vendors to ensure their compliance with laws, to assist the City in enforcement of laws, as well as to provide the City a means of identifying businesses which seek City contracts.

EXHIBIT B to FIRST RENEWAL AGREEMENT

**THE SCOPE OF SERVICES AND ROLES AND RESPONSIBILITIES OF EACH
PARTY**

(separately attached)

EXHIBIT B-1 to FIRST RENEWAL AGREEMENT

THE AMENDED SCOPE OF SERVICES AND ROLES AND RESPONSIBILITIES

ARTICLE I – Definitions

Page B-1:

In the table of definitions, after the definition of “NYC Specific Website”, add a definition of “Opioids” to read as follows: “Opioid analgesics or any drugs in the opiates therapeutic class except for the drugs listed in Attachment I of Exhibit B-1.”

ARTICLE III - Services

Page B-7:

Paragraph 8 – Delete the paragraph title in its entirety and replace with the following title:
“Prescription Drugs and Over the Counter Products; Prohibition of Certain Opioids”.

Add a new sub-paragraph (c) to read as follows:

“c. The Card may not be used to purchase Opioids. To this end, the Concessionaire must perform all necessary edits and coding to remove and prevent all prohibited Opioids from being purchased using the Card.”

ATTACHMENT I to EXHIBIT B-1

Exceptions to Definition of Opioids

(separately attached)

NDC	NDC_Numeric	Product_Name	Generic_Drug_Name	Strength_Per_Unit	UOM
00054017613	54017613	BUPRENORPHINE HYDROCHLORIDE	Buprenorphine Hydrochloride	2.00	MG
00054017713	54017713	BUPRENORPHINE HYDROCHLORIDE	Buprenorphine Hydrochloride	8.00	MG
00093537856	93537856	BUPRENORPHINE HYDROCHLORIDE	Buprenorphine Hydrochloride	2.00	MG
00093537956	93537956	BUPRENORPHINE HYDROCHLORIDE	Buprenorphine Hydrochloride	8.00	MG
00228315303	228315303	BUPRENORPHINE HYDROCHLORIDE	Buprenorphine Hydrochloride	8.00	MG
00228315603	228315603	BUPRENORPHINE HYDROCHLORIDE	Buprenorphine Hydrochloride	2.00	MG
00378092393	378092393	BUPRENORPHINE HYDROCHLORIDE	Buprenorphine Hydrochloride	2.00	MG
00378092493	378092493	BUPRENORPHINE HYDROCHLORIDE	Buprenorphine Hydrochloride	8.00	MG
12496127802	12496127802	SUBUTEX	Buprenorphine Hydrochloride	2.00	MG
12496131002	12496131002	SUBUTEX	Buprenorphine Hydrochloride	8.00	MG
35356055530	35356055530	BUPRENORPHINE HYDROCHLORIDE	Buprenorphine Hydrochloride	2.00	MG
35356055630	35356055630	BUPRENORPHINE HYDROCHLORIDE	Buprenorphine Hydrochloride	8.00	MG
43063066706	43063066706	BUPRENORPHINE HYDROCHLORIDE	Buprenorphine Hydrochloride	8.00	MG
49999063830	49999063830	SUBUTEX	Buprenorphine Hydrochloride	2.00	MG
49999063930	49999063930	SUBUTEX	Buprenorphine Hydrochloride	8.00	MG
50383092493	50383092493	BUPRENORPHINE HYDROCHLORIDE	Buprenorphine Hydrochloride	2.00	MG
50383093093	50383093093	BUPRENORPHINE HYDROCHLORIDE	Buprenorphine Hydrochloride	8.00	MG
54569657800	54569657800	BUPRENORPHINE HYDROCHLORIDE	Buprenorphine Hydrochloride	8.00	MG
55700030230	55700030230	BUPRENORPHINE HYDROCHLORIDE	Buprenorphine Hydrochloride	2.00	MG
55700030330	55700030330	BUPRENORPHINE HYDROCHLORIDE	Buprenorphine Hydrochloride	8.00	MG
63629409201	63629409201	SUBUTEX	Buprenorphine Hydrochloride	8.00	MG
63874117303	63874117303	SUBUTEX	Buprenorphine Hydrochloride	8.00	MG
63874117403	63874117403	SUBUTEX	Buprenorphine Hydrochloride	2.00	MG
68258299103	68258299103	BUPRENORPHINE HYDROCHLORIDE	Buprenorphine Hydrochloride	8.00	MG
68308020230	68308020230	BUPRENORPHINE HYDROCHLORIDE	Buprenorphine Hydrochloride	2.00	MG
68308020830	68308020830	BUPRENORPHINE HYDROCHLORIDE	Buprenorphine Hydrochloride	8.00	MG
62756045983	62756045983	BUPRENORPHINE HYDROCHLORIDE	Buprenorphine Hydrochloride	2.00	MG
43063075306	43063075306	BUPRENORPHINE HYDROCHLORIDE	Buprenorphine Hydrochloride	8.00	MG
53217024630	53217024630	BUPRENORPHINE HYDROCHLORIDE	Buprenorphine Hydrochloride	8.00	MG
62756046083	62756046083	BUPRENORPHINE HYDROCHLORIDE	Buprenorphine Hydrochloride	8.00	MG
54123090730	54123090730	ZUBSOLV	Buprenorphine/Naloxone	0.70	MG
50268014411	50268014411	BUPRENORPHINE-NALOXONE	Buprenorphine/Naloxone	2.00	MG
50268014415	50268014415	BUPRENORPHINE-NALOXONE	Buprenorphine/Naloxone	2.00	MG

MENT I: Exceptions to Definition of Opioids

60429058633	60429058633	BUPRENORPHINE-NALOXONE	Buprenorphine/Naloxone	2.00	MG
50268014511	50268014511	BUPRENORPHINE-NALOXONE	Buprenorphine/Naloxone	8.00	MG
50268014515	50268014515	BUPRENORPHINE-NALOXONE	Buprenorphine/Naloxone	8.00	MG
60429058733	60429058733	BUPRENORPHINE-NALOXONE	Buprenorphine/Naloxone	8.00	MG
00054018813	54018813	BUPRENORPHINE-NALOXONE	Buprenorphine/naloxone	2.00	MG
00054018913	54018913	BUPRENORPHINE-NALOXONE	Buprenorphine/naloxone	8.00	MG
00093572056	93572056	BUPRENORPHINE-NALOXONE	Buprenorphine/naloxone	2.00	MG
00093572156	93572156	BUPRENORPHINE-NALOXONE	Buprenorphine/naloxone	8.00	MG
00228315403	228315403	BUPRENORPHINE-NALOXONE	Buprenorphine/naloxone	2.00	MG
00228315473	228315473	BUPRENORPHINE-NALOXONE	Buprenorphine/naloxone	2.00	MG
00228315503	228315503	BUPRENORPHINE-NALOXONE	Buprenorphine/naloxone	8.00	MG
00228315573	228315573	BUPRENORPHINE-NALOXONE	Buprenorphine/naloxone	8.00	MG
00406192303	406192303	BUPRENORPHINE-NALOXONE	Buprenorphine/naloxone	2.00	MG
00406192403	406192403	BUPRENORPHINE-NALOXONE	Buprenorphine/naloxone	8.00	MG
00490005100	490005100	SUBOXONE	Buprenorphine/naloxone	2.00	MG
00490005130	490005130	SUBOXONE	Buprenorphine/naloxone	2.00	MG
00490005160	490005160	SUBOXONE	Buprenorphine/naloxone	2.00	MG
00490005190	490005190	SUBOXONE	Buprenorphine/naloxone	2.00	MG
12496120201	12496120201	SUBOXONE	Buprenorphine/naloxone	2.00	MG
12496120203	12496120203	SUBOXONE	Buprenorphine/naloxone	2.00	MG
12496120401	12496120401	SUBOXONE	Buprenorphine/naloxone	4.00	MG
12496120403	12496120403	SUBOXONE	Buprenorphine/naloxone	4.00	MG
12496120801	12496120801	SUBOXONE	Buprenorphine/naloxone	8.00	MG
12496120803	12496120803	SUBOXONE	Buprenorphine/naloxone	8.00	MG
12496121201	12496121201	SUBOXONE	Buprenorphine/naloxone	12.00	MG
12496121203	12496121203	SUBOXONE	Buprenorphine/naloxone	12.00	MG
12496128302	12496128302	SUBOXONE	Buprenorphine/naloxone	2.00	MG
12496130602	12496130602	SUBOXONE	Buprenorphine/naloxone	8.00	MG
16590066605	16590066605	SUBOXONE	Buprenorphine/naloxone	2.00	MG
16590066630	16590066630	SUBOXONE	Buprenorphine/naloxone	2.00	MG
16590066705	16590066705	SUBOXONE	Buprenorphine/naloxone	8.00	MG
16590066730	16590066730	SUBOXONE	Buprenorphine/naloxone	8.00	MG
16590066790	16590066790	SUBOXONE	Buprenorphine/naloxone	8.00	MG
23490927003	23490927003	SUBOXONE	Buprenorphine/naloxone	8.00	MG

23490927006	23490927006	SUBOXONE	Buprenorphine/naloxone	8.00	MG
23490927009	23490927009	SUBOXONE	Buprenorphine/naloxone	8.00	MG
35356000407	35356000407	SUBOXONE	Buprenorphine/naloxone	8.00	MG
35356000430	35356000430	SUBOXONE	Buprenorphine/naloxone	8.00	MG
42291017430	42291017430	BUPRENORPHINE-NALOXONE	Buprenorphine/naloxone	2.00	MG
42291017530	42291017530	BUPRENORPHINE-NALOXONE	Buprenorphine/naloxone	8.00	MG
43063018407	43063018407	SUBOXONE	Buprenorphine/naloxone	8.00	MG
43063018430	43063018430	SUBOXONE	Buprenorphine/naloxone	8.00	MG
49999039507	49999039507	SUBOXONE	Buprenorphine/naloxone	2.00	MG
49999039515	49999039515	SUBOXONE	Buprenorphine/naloxone	2.00	MG
49999039530	49999039530	SUBOXONE	Buprenorphine/naloxone	2.00	MG
50383028793	50383028793	BUPRENORPHINE-NALOXONE	Buprenorphine/naloxone	8.00	MG
50383029493	50383029493	BUPRENORPHINE-NALOXONE	Buprenorphine/naloxone	2.00	MG
52959030430	52959030430	SUBOXONE	Buprenorphine/naloxone	8.00	MG
52959074930	52959074930	SUBOXONE	Buprenorphine/naloxone	2.00	MG
53217013830	53217013830	BUPRENORPHINE-NALOXONE	Buprenorphine/naloxone	8.00	MG
54123011430	54123011430	ZUBSOLV	Buprenorphine/naloxone	11.40	MG
54123091430	54123091430	ZUBSOLV	Buprenorphine/naloxone	1.40	MG
54123092930	54123092930	ZUBSOLV	Buprenorphine/naloxone	2.90	MG
54123095730	54123095730	ZUBSOLV	Buprenorphine/naloxone	5.70	MG
54123098630	54123098630	ZUBSOLV	Buprenorphine/naloxone	8.60	MG
54569549600	54569549600	SUBOXONE	Buprenorphine/naloxone	2.00	MG
54569573900	54569573900	SUBOXONE	Buprenorphine/naloxone	8.00	MG
54569573901	54569573901	SUBOXONE	Buprenorphine/naloxone	8.00	MG
54569573902	54569573902	SUBOXONE	Buprenorphine/naloxone	8.00	MG
54569639900	54569639900	SUBOXONE	Buprenorphine/naloxone	8.00	MG
54569640800	54569640800	BUPRENORPHINE-NALOXONE	Buprenorphine/naloxone	8.00	MG
54868570700	54868570700	SUBOXONE	Buprenorphine/naloxone	8.00	MG
54868570701	54868570701	SUBOXONE	Buprenorphine/naloxone	8.00	MG
54868570702	54868570702	SUBOXONE	Buprenorphine/naloxone	8.00	MG
54868570703	54868570703	SUBOXONE	Buprenorphine/naloxone	8.00	MG
54868570704	54868570704	SUBOXONE	Buprenorphine/naloxone	8.00	MG
54868575000	54868575000	SUBOXONE	Buprenorphine/naloxone	2.00	MG
55045378403	55045378403	SUBOXONE	Buprenorphine/naloxone	8.00	MG

55700014730	55700014730	SUBOXONE	Buprenorphine/naloxone	8.00	MG
55700018430	55700018430	BUPRENORPHINE-NALOXONE	Buprenorphine/naloxone	2.00	MG
55887031204	55887031204	SUBOXONE	Buprenorphine/naloxone	8.00	MG
55887031215	55887031215	SUBOXONE	Buprenorphine/naloxone	8.00	MG
59385001201	59385001201	BUNAVAIL	Buprenorphine/naloxone	2.10	MG
59385001230	59385001230	BUNAVAIL	Buprenorphine/naloxone	2.10	MG
59385001401	59385001401	BUNAVAIL	Buprenorphine/naloxone	4.20	MG
59385001430	59385001430	BUNAVAIL	Buprenorphine/naloxone	4.20	MG
59385001601	59385001601	BUNAVAIL	Buprenorphine/naloxone	6.30	MG
59385001630	59385001630	BUNAVAIL	Buprenorphine/naloxone	6.30	MG
60429058630	60429058630	BUPRENORPHINE-NALOXONE	Buprenorphine/naloxone	2.00	MG
60429058730	60429058730	BUPRENORPHINE-NALOXONE	Buprenorphine/naloxone	8.00	MG
63629403401	63629403401	SUBOXONE	Buprenorphine/naloxone	8.00	MG
63629403402	63629403402	SUBOXONE	Buprenorphine/naloxone	8.00	MG
63629403403	63629403403	SUBOXONE	Buprenorphine/naloxone	8.00	MG
63874108403	63874108403	SUBOXONE	Buprenorphine/naloxone	8.00	MG
63874108503	63874108503	SUBOXONE	Buprenorphine/naloxone	2.00	MG
65162041503	65162041503	BUPRENORPHINE-NALOXONE	Buprenorphine/naloxone	8.00	MG
65162041603	65162041603	BUPRENORPHINE-NALOXONE	Buprenorphine/naloxone	2.00	MG
66336001530	66336001530	SUBOXONE	Buprenorphine/naloxone	2.00	MG
66336001630	66336001630	SUBOXONE	Buprenorphine/naloxone	8.00	MG
68071138003	68071138003	SUBOXONE	Buprenorphine/naloxone	8.00	MG
68071151003	68071151003	SUBOXONE	Buprenorphine/naloxone	2.00	MG
68258299903	68258299903	SUBOXONE	Buprenorphine/naloxone	2.00	MG



NEW YORK CITY DEPARTMENT OF

HEALTH AND MENTAL HYGIENE

Oxiris Barbot, MD

Commissioner

TO: All Borough Presidents
All Community Boards

FROM: Christian Diaz 
Assistant Commissioner, Finance, Administration and Services
Center for Health Equity and Community Wellness
Department of Health and Mental Hygiene

SUBJECT: Notice of Joint Public Hearing, December 9, 2019: re Amendment of the concession agreement between the New York City Department of Health and Mental Hygiene and OptumRx Discount Card Services, LLC (formerly known as Catamaran Discount Card Services, LLC) to develop, operate and administer the NYC Drug Discount Card Program available to all New York City residents

DATE: November 20, 2019

NOTICE OF A JOINT PUBLIC HEARING of the Franchise and Concession Review Committee and the New York City Department of Health and Mental Hygiene to be held on December 9, 2019 at 2 Lafayette Street, 14th Floor Auditorium, Borough of Manhattan, commencing at 2:30 p.m. relative to:

AMENDMENT of the concession agreement between the New York City Department of Health and Mental Hygiene and OptumRx Discount Card Services, LLC (formally known as Catamaran Discount Card Services, LLC) for the development, operation and administration of the NYC Drug Discount Card Program available to all New York City residents. The amendment extends the expiration date of the concession agreement from August 16, 2018 to December 31, 2021.

A draft copy of the amendment may be reviewed or obtained at no cost commencing November 22, 2019 through December 9, 2019, between the hours of 9:00 a.m. and 5 p.m., excluding weekends and holidays at the New York City Department of Health and Mental Hygiene, Office of Contracts, located at 42-09 28th Street, 17th Floor, Long Island City, NY 11101.

This location is accessible to individuals using wheelchairs or other mobility devices. For further information on accessibility or to make a request for accommodations, such as sign language interpretation services, please contact the Mayor's Office of Contract Services (MOCS) via e-mail at DisabilityAffairs@mocs.nyc.gov or via phone at (212) 788-0010. Any person requiring reasonable accommodation for the public hearing should contact MOCS at least three (3) business days in advance of the hearing to ensure availability. 

TELECOMMUNICATION DEVICE FOR THE DEAF (TDD) 212-504-4115

CONCESSION AGREEMENT RECOMMENDATION FOR AWARD MEMORANDUM COVER SHEET

(Attach, in the following order, applicable CRFA Memo, Responsibility Determination Form, approved CPSR Cover Sheet and, if the selection procedure was not CSB, the CPSR Memo and CCPO Memo (if applicable))

AGENCY: NYC Department of Health and Mental Hygiene ("DOHMH")	RECOMMENDED CONCESSIONAIRE Name: <u>OptumRx Discount Card Services, LLC (f/k/a Catamaran Discount Card Services, LLC)</u> Address: <u>1600 McConnor Parkway, Schaumburg, IL 60173</u> Telephone # <u>720-482-3726</u> <input checked="" type="checkbox"/> EIN <input type="checkbox"/> SSN # <u>31-1728846</u> Not-for-Profit Organization <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No Certified by DSBS as M/WBE <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No	CONCESSION TITLE/ DESCRIPTION: To develop, operate and administer the NYC Drug Discount Card Program available to all New York City residents. CONCESSION I.D.# <u>11HM000701R2T03</u>
# VOTES required for proposed action = <u>4</u> <input type="checkbox"/> N/A		

LOCATION OF CONCESSION SITE(S*) Address _____ N/A
*Attach additional sheet **Borough** _____ **C.B.** _____ **Block #** _____ **Lot #** _____

SELECTION PROCEDURE
 (*CCPO approval of CRFA required)

Competitive Sealed Bids
 Competitive Sealed Proposals* (FCRC approved Agency request to deviate from final recommendation of the Selection Committee on ___/___/___.)
 Different Selection Procedure: * (Sole Source Agreement Other Amendment to the existing concession agreement between DOHMH and OptumRx Discount Card Services, LLC (formerly known as Catamaran Discount Card Services, LLC.))
 > FCRC approved different selection procedure on 10/12/2018
 Negotiated Concession*

<p align="center">CONCESSION AGREEMENT TERM</p> Initial Term: From <u>02/17/2015</u> To <u>08/16/2018</u> Renewal Option(s) Term: <u>None</u> Total Potential Term: <u>08/16/2018 to 12/31/2021</u> <input type="checkbox"/> * >20 years – FCRC unanimously approved term on ___/___/___	<p align="center">ANNUAL REVENUE (Check all that apply) (<input type="checkbox"/> Additional sheet (<input type="checkbox"/>s) attached)</p> <input type="checkbox"/> Annual Fee(s) \$ _____ <input type="checkbox"/> % Gross Receipts _____% <input type="checkbox"/> The Greater of Annual Minimum Fee(s of \$_____ v. _____% of Gross Receipts <input checked="" type="checkbox"/> Other <u>DOHMH is required to operate a drug discount card program available to all NYC residents pursuant to Local Law 19 of 2005. In 2011, OptumRx was awarded a concession to develop, operate, and administer the NYC Drug Discount Card Program without charge to the City. Although there is no revenue received by the City, the benefit to DOHMH is the receipt of these services without a cost to the City. OptumRx will continue to operate and administer the Program at no charge to the City.</u>
---	---

NOTIFICATION REQUIREMENTS

Subject concession was awarded by CSB or CSP. YES NO

If YES, check the applicable box(es) below:

The subject concession is a Significant Concession and the Agency completed its consultations with each affected CB/BP regarding the scope of the solicitation by ___/___/___, which was at least 30 days prior to its issuance.

The subject concession is a Significant Concession and the Agency included this concession in the Agency's Plan and completed consultations with each affected CB/BP pursuant to §1-10 of the Concession Rules.

The subject concession was determined not to be a Major Concession and the Agency sent notification of such determination to each affected CB/BP by ___/___/___, which was at least 40 days prior to issuance of the solicitation.

If NO, check the applicable box below:

The Agency certifies that each affected CB/BP received written notice by 08/29/2018, which was at least 40 days in advance of the FCRC meeting on 10/12/2018 at which the agency sought and received approval to use a different selection procedure.

The Agency certifies that each affected CB/BP received written notice on ___/___/___, at the time that a notice of intent to enter into negotiations was published for the subject concession, and provided a copy of such notification to the members of the Committee within five days on ___/___/___.

The Agency certifies that based on exigent circumstances the FCRC unanimously approved waiver of advance written notice to each affected CB/BP on ___/___/___.

Law Department approved concession agreement on _____

Award is a major concession. YES NO

If YES, award was approved pursuant to Sections 197-c and 197-d of the NYC Charter as follows:

CPC approved on ___/___/___ City Council approved on ___/___/___ or N/A

AUTHORIZED AGENCY STAFF

This is to certify that the information presented herein is accurate and that I find the proposed concessionaire to be responsible and approve of the award of the subject concession agreement.

If the concession was awarded by other than CSB or CSP, additionally check the applicable box below:

The concession was approved by the FCRC on ___/___/___.

The concession was not subject to the approval of the FCRC because it has a term of <30 days and is not subject to renewal.

Name _____ **Title** _____

Signature _____ **Date** ___/___/___

CERTIFICATE OF PROCEDURAL REQUISITES

This is to certify that the agency has complied with the prescribed procedural requisites for award of the subject concession agreement.

Signature _____ **Date** ___/___/___

City Chief Procurement Officer

**RECOMMENDATION FOR AWARD OF CONCESSION AGREEMENT MEMORANDUM:
CONCESSION AGREEMENT AWARDED BY OTHER THAN CSB OR CSP**

SUMMARY OF PROPOSED CONCESSION USE (Attach Proposed Agreement)

New York City Department of Health and Mental Hygiene ("DOHMH") is seeking Franchise and Concession Review Committee ("FCRC") approval to use a different procedure, pursuant to Section 1-16 of the Concession Rules of the City of New York ("Concession Rules"), to amend its current Concession Agreement with OptumRx Discount Card Services, LLC. (formerly known as Catamaran Discount Card Services, LLC) to develop, operate and administer the NYC Drug Discount Card Program available to all New York City residents.

Instructions: Provide all information requested below; check all applicable boxes.

A. SELECTION PROCEDURE

Sole Source

Other ***Describe:*** DOHMH is seeking FCRC approval to use a different procedure, pursuant to Section 1-16 of the Concession rules, to amend its current Concession Agreement with OptumRx Discount Card Services, LLC. (formerly known as Catamaran Discount Card Services, LLC) for the development, operation and administration of the NYC Drug Discount Card Program available to all New York City residents.

B. NEGOTIATIONS

Instructions: Describe the nature of negotiations conducted, including negotiations with respect to the amount of revenue offered.

During negotiations it became apparent that a second extension of 18-months as originally anticipated was not going to be sufficient to complete the RFP process and enter into a new concession agreement. During the first extension of 18 months, DOHMH conducted extensive research to inform the next iteration of the Big Apple RX card, identified potential strategies to strengthen opioid controls, and worked with legal teams from both the City and the concessionaire to resolve issues concerning transition planning. In that time, DOHMH also worked diligently to solidify a provision to carve out opioid prescriptions. The foregoing efforts demanded extensive time, technical and legal expertise, negotiation with the existing concessionaire, OptumRx Discount Card Services, LLC., and input from agency and city leadership. Furthermore, the development and review of the RFP was time and resource intensive. Due to the now crowded landscape of prescription drug discount card programs and skyrocketing prices for prescription drugs, the City anticipates the number of interested RFP respondents, time needed for review and selection, and negotiation of a final concession agreement would considerably lengthen the time needed for the RFP process. Therefore, DOHMH is requesting an extension of the current concession from August 16, 2018 to December 31, 2021.

DOHMH has had a professional relationship with OptumRx Discount Card Services, LLC. since 2015. While there is no actual contract in place as of August 2018, OptumRx has been operating in good faith, and is willing to continue to operate and administer the NYC Drug Discount Card Program during the requested extension period. The amended Concession Agreement would extend the expiration date of the current Concession Agreement from August 16, 2018 to December 31, 2021 and would modify the scope of services to prohibit use of the Big Apple RX card for certain opioid prescriptions. DOHMH intends to undertake a new RFP process to solicit a new concessionaire to develop, operate and administer the NYC Drug Discount Card Program, and anticipates a new award will be in place by the expiration of this extension period.

C. BASIS FOR AWARD (If sole source award, attach the offer; if other than a sole source award, attach the three highest rated offers, if applicable.)

The agency determined that amendment of the concession is in the best interest of the City because:

DOHMH believes that the City will be best served by extending the Concession Agreement with OptumRx Discount Card Services, LLC., to enable the residents of New York City to continue to have access to pharmaceutical drugs at discount prices without interruption while DOHMH undertakes a new RFP process to solicit a concessionaire to develop, operate and administer the NYC Drug Discount Card Program.

Currently, over 1 million IDNYC cards have been issued by the City with the BigAppleRX benefit feature on the card, enabling cardholders to purchase pharmaceutical drugs at discount prices provided by OptumRx (also referred to as "BigAppleRX provider"). Those IDNYC cards will remain in effect until 5 years after their effective date. Given that the BigApple RX benefit is linked to these IDNYC cards, transitioning to a new provider will be administratively complicated and time consuming. Therefore, DOHMH believes that the City will be best served by an extension to the current concession agreement with OptumRx to enable the residents of New York City to continue to have access to pharmaceutical drugs at discount prices without interruption while DOHMH initiates a new RFP process to select a new concessionaire.

D. PUBLIC HEARING **N/A – Subject award NOT a significant concession**

1. Publication & Distribution of Public Hearing Notice

Subject concession is a **Citywide** concession and Agency hereby certifies that a notice containing a summary of the terms and conditions of the proposed concession and stating the time, date and location of the public hearing was published once in the City Record on November 22, 2019 which was not less than 15 days prior to the hearing date or a shorter period approved by the CCPO and was given to each affected CB-BP and the Committee Members on December 9, 2019, which was not less than 15 days prior to the hearing date. Agency also published a public hearing notice twice in the two newspapers indicated below. A copy of each such notice was sent to each affected CB-BP by November 20, 2019.

New York Post, a NYC citywide newspaper on December 4, 2019 and December 6, 2019

New York Daily, a NYC citywide newspaper on December 4, 2019 and December 6,

2019
OR

Subject concession is **NOT a Citywide** concession and Agency hereby certifies that a notice containing a summary of the terms and conditions of the proposed concession and stating the time, date and location of the public hearing was published once in the City Record on ___/___/___, which was not less than 15 days prior to the hearing date or a shorter period approved by the CCPO and was given to each affected CB-BP and the Committee Members on ___/___/___, which was not less than 15 days prior to the hearing date. Agency additionally published a public hearing notice and summary of the terms and conditions of the proposed agreement twice in two newspapers indicated below. A copy of each such notice containing a summary of the terms and conditions of the proposed agreement was sent to each affected CB-BP by ___/___/___.

_____, a NYC local newspaper published in the affected borough(s) on ___/___/___ and ___/___/___.

_____, a NYC local newspaper published in the affected borough(s) on ___/___/___ and ___/___/___.

2. Public Hearing Date, Exception to Public Hearing Requirement

A Public Hearing was conducted on December 9, 2019.

OR

The Agency certifies that the total annual revenue to the City from the subject concession does not exceed one million dollars and a Public Hearing was not conducted because, pursuant to §1-13(q)(2) of the Concession Rules, the Agency gave notice of the hearing and did not receive any written requests to speak at such hearing or requests from the Committee that the Agency appear at the hearing. Furthermore, the Agency certifies that it published a notice in the City Record canceling such hearing on ___/___/___ and sent a copy of that notice to all Committee Members.

CITY OF NEW YORK

FRANCHISE AND CONCESSION REVIEW COMMITTEE

(Cal. No. X)

RESOLVED, that the Franchise and Concession Review Committee authorizes the New York City Department of Health and Mental Hygiene (“DOHMH”) to utilize a different procedure, pursuant to Section 1-16 of the Concession Rules of the City of New York, to amend the concession agreement with OptumRx Discount Card Services, LLC (formerly known as Catamaran Discount Card Services, LLC) to develop, operate and administer the NYC Drug Discount Card Program available to all New York City residents. The amended concession agreement, among other things, extends the expiration date of the concession agreement from August 16, 2018 to December 31, 2021.

**THIS IS A TRUE COPY OF THE RESOLUTION ADOPTED BY THE
FRANCHISE AND CONCESSION REVIEW COMMITTEE ON**

December 11, 2019

Date: _____

Signed: _____

Title: Director of the Mayor’s Office of Contract Services

**SECOND AMENDMENT TO
FIRST RENEWAL AGREEMENT**

of

CONCESSION AGREEMENT

BETWEEN

OPTUMRX DISCOUNT CARD SERVICES, LLC

AND

CITY OF NEW YORK

Acting by and through its

DEPARTMENT OF HEALTH & MENTAL HYGIENE

for

**THE OPERATION AND ADMINISTRATION OF THE
NEW YORK CITY PRESCRIPTION DRUG DISCOUNT CARD PROGRAM**

Concession ID #: 19HO011401R0X00

SECOND AMENDMENT TO THE FIRST RENEWAL AGREEMENT (“Second Amendment”) effective as of August 16, 2018 (“the Effective Date”), between the City of New York (“City”) acting by and through its **Department of Health and Mental Hygiene** (“the Department” or “DOHMH”), having its principal office at 42-09 28th Street, Long Island City, New York 11101, and **OptumRx Discount Card Services, LLC**, a Delaware pharmacy benefit management company (“Concessionaire” or “OptumRx”), having a principal office at 1600 McConnor Parkway, Schaumburg, Illinois 60173 (each “a Party”, together, “the Parties”).

WITNESSETH

WHEREAS, the Department, pursuant to Local Law 19 of 2005 “Prescription Drug Discount Card Act” (“Local Law 19”), is required to develop a drug discount card program to be made available to all City residents, known as the NYC Prescription Drug Discount Card Program (“the Program”); and

WHEREAS, Local Law 19 allows the Department to enter into an agreement for the services of a Program administrator, and the City has determined that such agreement shall be in the form of a concession; and

WHEREAS, the Department entered into a concession agreement with HealthTran, LLC (d/b/a HealthTrans), as concessionaire (Concession ID#: 11HM000700R0X00), to develop, operate and administer the Program for the initial term of three (3) years, from February 17, 2011 through February 16, 2014 (“Initial Term”), with the option to renew for one or more periods of twelve (12) months that in the aggregate do not exceed three (3) years (“Original Concession Agreement”); and

WHEREAS, during the Initial Term of the Original Concession Agreement, the concessionaire was acquired by SXC Health Solutions Corp., which subsequently changed its name to Catamaran Corporation, and as a result thereof the concessionaire’s name was changed to Catamaran Corporation; and

WHEREAS, the Original Concession Agreement was renewed for a first renewal term of one (1) year, from February 17, 2014 through February 16, 2015, by amending and restating the Agreement and including therein the remaining renewals that in the aggregate do not exceed two (2) years (“First Renewal Agreement”, Concession ID#: 11HM000701R1X00); and

WHEREAS, the concessionaire in the First Renewal Agreement was Catamaran PBM of Colorado, a subsidiary of Catamaran Corporation, and during the First Renewal Agreement the concessionaire changed its name to Catamaran Discount Card Services, LLC (hereinafter “Catamaran”); and

WHEREAS, the First Renewal Agreement was renewed for a second renewal term of two (2) years, from February 17, 2015 through February 16, 2017, by a Notice to Renew letter provided

in accordance with the provisions of the First Renewal Agreement (“Second Renewal Agreement”, Concession ID#:11HM000701R2X00); and

WHEREAS, during the term of the Second Renewal Agreement, the concessionaire changed its name from Catamaran Discount Card Services, LLC to OptumRx Discount Card Services, LLC, due to the acquisition of Catamaran by OptumRx; and

WHEREAS, upon the expiration of the Second Renewal Agreement, there were no further renewals provided for under the First Renewal Agreement; and

WHEREAS, the Department intends to undertake a competitive request for proposal (“RFP”) process to solicit a new concessionaire to operate and administer the Program; and

WHEREAS, in order for the City to continue to comply with Local Law 19 and serve the needs of NYC residents without interruption during the RFP process, the Department sought and received authorization from the Franchise and Concession Review Committee (“FCRC”) to use a different procedure to enter into an Amendment to the First Renewal Agreement (Concession ID#: 11HM000701R2T01), pursuant to which OptumRx continued to operate and administer the program for an additional eighteen (18) months, from February 16, 2017 to August 16, 2018 (“First Amendment”); and

WHEREAS, the Department anticipated releasing an RFP and selecting a new concessionaire on or before August 2018, but because of unforeseen delays in the development of the RFP due to changes in the scope of services, the Department now anticipates that a new concessionaire will be in place by December 31, 2021; and

WHEREAS, in order for the City to continue to comply with Local Law 19 and serve the needs of NYC residents during the RFP process, it will be necessary to extend the First Renewal Agreement from August 16, 2018 through December 31, 2021 and to amend the scope of services (this Second Amendment) to continue to provide such services to NYC residents without interruption; and

WHEREAS, OptumRx is willing to continue to provide the services of operating and administering the Program, and the Parties desire to amend the terms of the First Renewal Agreement, subject to and in accordance with the terms of this Second Amendment; and

WHEREAS, the FCRC has authorized the Department to use a different procedure to enter into this Second Amendment.

NOW THEREFORE, in consideration of the mutual promises herein contained, the Parties hereby agree as follows:

1. Unless otherwise noted, all capitalized terms referenced herein shall have the meanings ascribed thereto in the First Renewal Agreement.
2. Section 3.03 of the First Renewal Agreement, as added by the First Amendment, is hereby deleted in its entirety and replaced with the following”

“Section 3.03 Extension: This Agreement shall be extended from February 16, 2017, the last day of the second Renewal Term exercised pursuant to Section 3.02 above, to August 16, 2018, for a period of eighteen (18) months, unless sooner terminated pursuant to the provisions hereof (“First Amendment Extension Term”). This Agreement shall be extended from August 16, 2018 to December 31, 2021, unless sooner terminated pursuant to the provisions hereof (“Second Amendment Extension Term”). Notwithstanding any inconsistent provision of this Agreement, the Services shall continue uninterrupted and in accordance with the provisions of this Agreement during the First Amendment and Second Amendment Extension Terms.”

3. Subsection (a) of Article 22 of the First Renewal Agreement is hereby deleted in its entirety and replaced with the following:

(a) All notices, directions and communications by either party shall be in writing and, except as otherwise specified in this Agreement, directed to the address of the parties as follows:

New York City
Dept. of Health & Mental Hygiene
42-09 28th Street, WS 12-10
Long Island City, NY 11101

Attn: Cynthia Mont-Burbon
Director of Contracts
Prevention & Primary Care Administration

OptumRx Discount Card Services, LLC

1600 McConnor Parkway
Schaumburg, Illinois 60173

Attn: Michael Oshins
Vice President,
Sales & Business Development
Pharmacy Discount Services

With a copy to:

Vernon Blair
Deputy General Counsel
42-09 28th Street, WS 14-93
Long Island City, NY 11101

With a copy to:

General Counsel
1600 McConnor Parkway
Schaumburg, Illinois 60173

4. Exhibit B of the First Renewal Agreement (The Scope of Services and Roles and Responsibilities of Each Party) (attached for convenience) is hereby amended as outlined in Exhibit B-1 of the First Renewal Agreement (The Amended Scope of Services and Roles and Responsibilities of Each Party) attached hereto and made a part hereof. All references in the First Renewal Agreement to “Exhibit B,” the “Scope of Services”, or the “Services” shall be deemed to also refer to Exhibit B-1.
5. Except as expressly amended herein, all terms and conditions of the First Renewal Agreement, as previously amended, shall remain unchanged and in full force and effect.

6. This Amendment shall take effect on, and shall be retroactive to, August 16, 2018, subject to compliance with all applicable processes including registration with the New York City Comptroller pursuant to Section 328 of the New York City Charter.

Attachments

Exhibit B to First Renewal Agreement: The Scope of Services and Roles and Responsibilities of Each Party (attached for convenience)

Exhibit B-1 to First Renewal Agreement: The Amended Scope of Services and Roles and Responsibilities of Each Party

Attachment I to Exhibit B-1: Exceptions to Definition of Opioids

IN WITNESS WHEREOF, the City and the Concessionaire have caused this Second Amendment to be executed in triplicate by their duly authorized representatives as of the day and year written below.

**CITY OF NEW YORK
DEPARTMENT OF HEALTH AND MENTAL HYGIENE**

BY: _____

NAME: Judi R. Soehren
TITLE: Agency Chief Contracting Officer

Date: _____

**OPTUMRX
DISCOUNT CARD SERVICES, LLC**

By: _____

NAME: _____
TITLE: _____

Date: _____

APPROVED AS TO FORM
CERTIFIED AS TO LEGAL AUTHORITY

Acting Corporation Counsel

Date: _____

NYC DEPARTMENT OF HEALTH AND MENTAL HYGIENE

STATE OF NEW YORK)

ss:

COUNTY OF NEW YORK)

On this _____ day of _____ 2019 before me personally came Judi Soehren, to me known and known to me to be the Agency Chief Contracting Officer of the **Department of Health and Mental Hygiene** of the City of New York, the person described in who, as Agency Chief Contracting Officer executed, the foregoing agreement, and she duly acknowledged to me that she executed the same on behalf of the City of New York and DOHMH of Health and Mental Hygiene for the purpose herein mentioned.

Notary Public or Commissioner of Deeds

OPTUMRX DISCOUNT CARD SERVICES, LLC

STATE OF)

ss:

COUNTY OF)

On this ____ day of _____, 2019 before me personally came _____ who being by me duly sworn, did depose and say that (s)he resides in the City of _____; that (s)he is the _____ of **OptumRx Discount Card Services, LLC**, the corporation described in and which executed the foregoing instrument; that (s)he knows the seal of said Corporation; that the seal affixed to the said instrument is such corporate seal; that it was so affixed by order of the Board of Directors of said Corporation; and that (s)he signed his/her name thereto by like order for the purposes therein mentioned.

Notary Public or Commissioner of Deeds

AFFIRMATION

The undersigned proposer or bidder Affirms and declares that said proposer or bidder is not in arrears to the City of New York upon debt, contract or taxes and is not a defaulter, as surety or otherwise, upon obligation to the City of New York, and has not been declared not responsible, or disqualified, by any agency of the City of New York, nor is there any proceeding pending relating to the responsibility or qualification of the proposer or bidder to receive public contracts except

_____.

Full name of proposer or bidder: _____

Address: _____

City: _____ State: _____ Zip: _____

CHECK ONE AND INCLUDE APPROPRIATE NUMBER:

() A -- Individual or Sole Proprietorship
SOCIAL SECURITY NUMBER

() B -- _____-_____-_____
Partnership, Joint Venture or other unincorporated organization
Employer Identification Number

() C -- _____-_____-_____
Corporation
Employer Identification Number

By: _____
Signature

Title

If a corporation, place seal here:

Must be signed by an officer or duly authorized representative.

Under the Federal Privacy Act the furnishing of Social Security Number by bidders on City contracts is voluntary. Failure to provide a Social Security Number will not result in a bidder's disqualification. Social Security Numbers will be used to identify bidders, proposers or vendors to ensure their compliance with laws, to assist the City in enforcement of laws, as well as to provide the City a means of identifying businesses which seek City contracts.

EXHIBIT B to FIRST RENEWAL AGREEMENT

**THE SCOPE OF SERVICES AND ROLES AND RESPONSIBILITIES OF EACH
PARTY**

(separately attached)

EXHIBIT B-1 to FIRST RENEWAL AGREEMENT

THE AMENDED SCOPE OF SERVICES AND ROLES AND RESPONSIBILITIES

ARTICLE I – Definitions

Page B-1:

In the table of definitions, after the definition of “NYC Specific Website”, add a definition of “Opioids” to read as follows: “Opioid analgesics or any drugs in the opiates therapeutic class except for the drugs listed in Attachment I of Exhibit B-1.”

ARTICLE III - Services

Page B-7:

Paragraph 8 – Delete the paragraph title in its entirety and replace with the following title:
“Prescription Drugs and Over the Counter Products; Prohibition of Certain Opioids”.

Add a new sub-paragraph (c) to read as follows:

“c. The Card may not be used to purchase Opioids. To this end, the Concessionaire must perform all necessary edits and coding to remove and prevent all prohibited Opioids from being purchased using the Card.”

ATTACHMENT I to EXHIBIT B-1

Exceptions to Definition of Opioids

(separately attached)

NDC	NDC_Numeric	Product_Name	Generic_Drug_Name	Strength_Per_Unit	UOM	
00054017613	54017613	BUPRENORPHINE HYDROCHLORIDE	Buprenorphine Hydrochloride	2.00	MG	
00054017713	54017713	BUPRENORPHINE HYDROCHLORIDE	Buprenorphine Hydrochloride	8.00	MG	
00093537856	93537856	BUPRENORPHINE HYDROCHLORIDE	Buprenorphine Hydrochloride	2.00	MG	
00093537956	93537956	BUPRENORPHINE HYDROCHLORIDE	Buprenorphine Hydrochloride	8.00	MG	
00228315303	228315303	BUPRENORPHINE HYDROCHLORIDE	Buprenorphine Hydrochloride	8.00	MG	
00228315603	228315603	BUPRENORPHINE HYDROCHLORIDE	Buprenorphine Hydrochloride	2.00	MG	
00378092393	378092393	BUPRENORPHINE HYDROCHLORIDE	Buprenorphine Hydrochloride	2.00	MG	
00378092493	378092493	BUPRENORPHINE HYDROCHLORIDE	Buprenorphine Hydrochloride	8.00	MG	
12496127802	12496127802	SUBUTEX	Buprenorphine Hydrochloride	2.00	MG	
12496131002	12496131002	SUBUTEX	Buprenorphine Hydrochloride	8.00	MG	
35356055530	35356055530	BUPRENORPHINE HYDROCHLORIDE	Buprenorphine Hydrochloride	2.00	MG	
35356055630	35356055630	BUPRENORPHINE HYDROCHLORIDE	Buprenorphine Hydrochloride	8.00	MG	MENT I: Exceptions to Definition of Opioids
43063066706	43063066706	BUPRENORPHINE HYDROCHLORIDE	Buprenorphine Hydrochloride	8.00	MG	
49999063830	49999063830	SUBUTEX	Buprenorphine Hydrochloride	2.00	MG	
49999063930	49999063930	SUBUTEX	Buprenorphine Hydrochloride	8.00	MG	
50383092493	50383092493	BUPRENORPHINE HYDROCHLORIDE	Buprenorphine Hydrochloride	2.00	MG	
50383093093	50383093093	BUPRENORPHINE HYDROCHLORIDE	Buprenorphine Hydrochloride	8.00	MG	
54569657800	54569657800	BUPRENORPHINE HYDROCHLORIDE	Buprenorphine Hydrochloride	8.00	MG	
55700030230	55700030230	BUPRENORPHINE HYDROCHLORIDE	Buprenorphine Hydrochloride	2.00	MG	
55700030330	55700030330	BUPRENORPHINE HYDROCHLORIDE	Buprenorphine Hydrochloride	8.00	MG	
63629409201	63629409201	SUBUTEX	Buprenorphine Hydrochloride	8.00	MG	
63874117303	63874117303	SUBUTEX	Buprenorphine Hydrochloride	8.00	MG	
63874117403	63874117403	SUBUTEX	Buprenorphine Hydrochloride	2.00	MG	
68258299103	68258299103	BUPRENORPHINE HYDROCHLORIDE	Buprenorphine Hydrochloride	8.00	MG	
68308020230	68308020230	BUPRENORPHINE HYDROCHLORIDE	Buprenorphine Hydrochloride	2.00	MG	
68308020830	68308020830	BUPRENORPHINE HYDROCHLORIDE	Buprenorphine Hydrochloride	8.00	MG	
62756045983	62756045983	BUPRENORPHINE HYDROCHLORIDE	Buprenorphine Hydrochloride	2.00	MG	
43063075306	43063075306	BUPRENORPHINE HYDROCHLORIDE	Buprenorphine Hydrochloride	8.00	MG	
53217024630	53217024630	BUPRENORPHINE HYDROCHLORIDE	Buprenorphine Hydrochloride	8.00	MG	
62756046083	62756046083	BUPRENORPHINE HYDROCHLORIDE	Buprenorphine Hydrochloride	8.00	MG	
54123090730	54123090730	ZUBSOLV	Buprenorphine/Naloxone	0.70	MG	
50268014411	50268014411	BUPRENORPHINE-NALOXONE	Buprenorphine/Naloxone	2.00	MG	
50268014415	50268014415	BUPRENORPHINE-NALOXONE	Buprenorphine/Naloxone	2.00	MG	

60429058633	60429058633	BUPRENORPHINE-NALOXONE	Buprenorphine/Naloxone	2.00	MG
50268014511	50268014511	BUPRENORPHINE-NALOXONE	Buprenorphine/Naloxone	8.00	MG
50268014515	50268014515	BUPRENORPHINE-NALOXONE	Buprenorphine/Naloxone	8.00	MG
60429058733	60429058733	BUPRENORPHINE-NALOXONE	Buprenorphine/Naloxone	8.00	MG
00054018813	54018813	BUPRENORPHINE-NALOXONE	Buprenorphine/naloxone	2.00	MG
00054018913	54018913	BUPRENORPHINE-NALOXONE	Buprenorphine/naloxone	8.00	MG
00093572056	93572056	BUPRENORPHINE-NALOXONE	Buprenorphine/naloxone	2.00	MG
00093572156	93572156	BUPRENORPHINE-NALOXONE	Buprenorphine/naloxone	8.00	MG
00228315403	228315403	BUPRENORPHINE-NALOXONE	Buprenorphine/naloxone	2.00	MG
00228315473	228315473	BUPRENORPHINE-NALOXONE	Buprenorphine/naloxone	2.00	MG
00228315503	228315503	BUPRENORPHINE-NALOXONE	Buprenorphine/naloxone	8.00	MG
00228315573	228315573	BUPRENORPHINE-NALOXONE	Buprenorphine/naloxone	8.00	MG
00406192303	406192303	BUPRENORPHINE-NALOXONE	Buprenorphine/naloxone	2.00	MG
00406192403	406192403	BUPRENORPHINE-NALOXONE	Buprenorphine/naloxone	8.00	MG
00490005100	490005100	SUBOXONE	Buprenorphine/naloxone	2.00	MG
00490005130	490005130	SUBOXONE	Buprenorphine/naloxone	2.00	MG
00490005160	490005160	SUBOXONE	Buprenorphine/naloxone	2.00	MG
00490005190	490005190	SUBOXONE	Buprenorphine/naloxone	2.00	MG
12496120201	12496120201	SUBOXONE	Buprenorphine/naloxone	2.00	MG
12496120203	12496120203	SUBOXONE	Buprenorphine/naloxone	2.00	MG
12496120401	12496120401	SUBOXONE	Buprenorphine/naloxone	4.00	MG
12496120403	12496120403	SUBOXONE	Buprenorphine/naloxone	4.00	MG
12496120801	12496120801	SUBOXONE	Buprenorphine/naloxone	8.00	MG
12496120803	12496120803	SUBOXONE	Buprenorphine/naloxone	8.00	MG
12496121201	12496121201	SUBOXONE	Buprenorphine/naloxone	12.00	MG
12496121203	12496121203	SUBOXONE	Buprenorphine/naloxone	12.00	MG
12496128302	12496128302	SUBOXONE	Buprenorphine/naloxone	2.00	MG
12496130602	12496130602	SUBOXONE	Buprenorphine/naloxone	8.00	MG
16590066605	16590066605	SUBOXONE	Buprenorphine/naloxone	2.00	MG
16590066630	16590066630	SUBOXONE	Buprenorphine/naloxone	2.00	MG
16590066705	16590066705	SUBOXONE	Buprenorphine/naloxone	8.00	MG
16590066730	16590066730	SUBOXONE	Buprenorphine/naloxone	8.00	MG
16590066790	16590066790	SUBOXONE	Buprenorphine/naloxone	8.00	MG
23490927003	23490927003	SUBOXONE	Buprenorphine/naloxone	8.00	MG

23490927006	23490927006	SUBOXONE	Buprenorphine/naloxone	8.00	MG
23490927009	23490927009	SUBOXONE	Buprenorphine/naloxone	8.00	MG
35356000407	35356000407	SUBOXONE	Buprenorphine/naloxone	8.00	MG
35356000430	35356000430	SUBOXONE	Buprenorphine/naloxone	8.00	MG
42291017430	42291017430	BUPRENORPHINE-NALOXONE	Buprenorphine/naloxone	2.00	MG
42291017530	42291017530	BUPRENORPHINE-NALOXONE	Buprenorphine/naloxone	8.00	MG
43063018407	43063018407	SUBOXONE	Buprenorphine/naloxone	8.00	MG
43063018430	43063018430	SUBOXONE	Buprenorphine/naloxone	8.00	MG
49999039507	49999039507	SUBOXONE	Buprenorphine/naloxone	2.00	MG
49999039515	49999039515	SUBOXONE	Buprenorphine/naloxone	2.00	MG
49999039530	49999039530	SUBOXONE	Buprenorphine/naloxone	2.00	MG
50383028793	50383028793	BUPRENORPHINE-NALOXONE	Buprenorphine/naloxone	8.00	MG
50383029493	50383029493	BUPRENORPHINE-NALOXONE	Buprenorphine/naloxone	2.00	MG
52959030430	52959030430	SUBOXONE	Buprenorphine/naloxone	8.00	MG
52959074930	52959074930	SUBOXONE	Buprenorphine/naloxone	2.00	MG
53217013830	53217013830	BUPRENORPHINE-NALOXONE	Buprenorphine/naloxone	8.00	MG
54123011430	54123011430	ZUBSOLV	Buprenorphine/naloxone	11.40	MG
54123091430	54123091430	ZUBSOLV	Buprenorphine/naloxone	1.40	MG
54123092930	54123092930	ZUBSOLV	Buprenorphine/naloxone	2.90	MG
54123095730	54123095730	ZUBSOLV	Buprenorphine/naloxone	5.70	MG
54123098630	54123098630	ZUBSOLV	Buprenorphine/naloxone	8.60	MG
54569549600	54569549600	SUBOXONE	Buprenorphine/naloxone	2.00	MG
54569573900	54569573900	SUBOXONE	Buprenorphine/naloxone	8.00	MG
54569573901	54569573901	SUBOXONE	Buprenorphine/naloxone	8.00	MG
54569573902	54569573902	SUBOXONE	Buprenorphine/naloxone	8.00	MG
54569639900	54569639900	SUBOXONE	Buprenorphine/naloxone	8.00	MG
54569640800	54569640800	BUPRENORPHINE-NALOXONE	Buprenorphine/naloxone	8.00	MG
54868570700	54868570700	SUBOXONE	Buprenorphine/naloxone	8.00	MG
54868570701	54868570701	SUBOXONE	Buprenorphine/naloxone	8.00	MG
54868570702	54868570702	SUBOXONE	Buprenorphine/naloxone	8.00	MG
54868570703	54868570703	SUBOXONE	Buprenorphine/naloxone	8.00	MG
54868570704	54868570704	SUBOXONE	Buprenorphine/naloxone	8.00	MG
54868575000	54868575000	SUBOXONE	Buprenorphine/naloxone	2.00	MG
55045378403	55045378403	SUBOXONE	Buprenorphine/naloxone	8.00	MG

55700014730	55700014730	SUBOXONE	Buprenorphine/naloxone	8.00	MG
55700018430	55700018430	BUPRENORPHINE-NALOXONE	Buprenorphine/naloxone	2.00	MG
55887031204	55887031204	SUBOXONE	Buprenorphine/naloxone	8.00	MG
55887031215	55887031215	SUBOXONE	Buprenorphine/naloxone	8.00	MG
59385001201	59385001201	BUNAVAIL	Buprenorphine/naloxone	2.10	MG
59385001230	59385001230	BUNAVAIL	Buprenorphine/naloxone	2.10	MG
59385001401	59385001401	BUNAVAIL	Buprenorphine/naloxone	4.20	MG
59385001430	59385001430	BUNAVAIL	Buprenorphine/naloxone	4.20	MG
59385001601	59385001601	BUNAVAIL	Buprenorphine/naloxone	6.30	MG
59385001630	59385001630	BUNAVAIL	Buprenorphine/naloxone	6.30	MG
60429058630	60429058630	BUPRENORPHINE-NALOXONE	Buprenorphine/naloxone	2.00	MG
60429058730	60429058730	BUPRENORPHINE-NALOXONE	Buprenorphine/naloxone	8.00	MG
63629403401	63629403401	SUBOXONE	Buprenorphine/naloxone	8.00	MG
63629403402	63629403402	SUBOXONE	Buprenorphine/naloxone	8.00	MG
63629403403	63629403403	SUBOXONE	Buprenorphine/naloxone	8.00	MG
63874108403	63874108403	SUBOXONE	Buprenorphine/naloxone	8.00	MG
63874108503	63874108503	SUBOXONE	Buprenorphine/naloxone	2.00	MG
65162041503	65162041503	BUPRENORPHINE-NALOXONE	Buprenorphine/naloxone	8.00	MG
65162041603	65162041603	BUPRENORPHINE-NALOXONE	Buprenorphine/naloxone	2.00	MG
66336001530	66336001530	SUBOXONE	Buprenorphine/naloxone	2.00	MG
66336001630	66336001630	SUBOXONE	Buprenorphine/naloxone	8.00	MG
68071138003	68071138003	SUBOXONE	Buprenorphine/naloxone	8.00	MG
68071151003	68071151003	SUBOXONE	Buprenorphine/naloxone	2.00	MG
68258299903	68258299903	SUBOXONE	Buprenorphine/naloxone	2.00	MG